Drug intelligence / Profile preview

pravastatin + carvedilol + perindopril

Development stage
Unknown
Lead developer
Daiichi Sankyo
Modality
Small Molecules
Administration
Oral
01

Overview

This is a combination drug consisting of three active pharmaceutical ingredients: - **Pravastatin** is an HMG-CoA reductase inhibitor (statin) used to lower cholesterol and reduce the risk of cardiovascular events. - **Carvedilol** is a non-selective beta-adrenergic antagonist with additional alpha-1 blocking activity, used for treating hypertension, heart failure, and left ventricular dysfunction after myocardial infarction. It reduces blood pressure and cardiac workload by blocking adrenergic stimulation[2]. - **Perindopril** is an angiotensin-converting enzyme (ACE) inhibitor prodrug that lowers blood pressure by inhibiting the conversion of angiotensin I to angiotensin II, thereby reducing vasoconstriction and aldosterone-mediated volume expansion[8]. The combination targets multiple pathways involved in cardiovascular disease management—lipid lowering (pravastatin), sympathetic inhibition (carvedilol), and renin-angiotensin system blockade (perindopril). Such multi-drug regimens are often used in patients with comorbid hypertension, hypercholesterolemia, and heart failure or high cardiovascular risk. There may be additive or synergistic effects on blood pressure reduction when statins are combined with ACE inhibitors[4][6]. No single-pill formulation containing all three agents under a unique brand name appears to exist; this would be considered an off-label or custom polypharmacy approach.

02

Targets

ACE (Angiotensin Converting Enzyme)ADRB1 (β1)HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)ADRB2 (β2)ADRA1A (α1A)

Beyond the preview

Go deeper on pravastatin + carvedilol + perindopril.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on pravastatin + carvedilol + perindopril.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call